SCHEMBL25308772

SCHEMBL25308772

CC1(C)CC(c2ccc(Cl)cc2)=C(CCl)[C@H](O)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.43
PTGS2 P35354 4/20 0.43
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
BCL2L1 Q07817 1/20 0.32
ACHE P22303 1/20 0.32
LMNA P02545 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PTGES O14684 1/20 0.31
ALOX5 P09917 1/20 0.31
ALOX5AP P20292 1/20 0.31
SLC6A3 Q01959 3/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25308773 1.00 PTGS1 (0.43) PTGS1PTGS2SIRT2SIRT1CNR1
SCHEMBL1959392 0.69 PTGS2 (0.45) PTGS1PTGS2BCL2L1ACHESLC6A3
SCHEMBL1956706 0.68 PTGS1 (0.51) PTGS1PTGS2SIRT2SIRT1BCL2L1
SCHEMBL25309682 0.68 PTGS1 (0.51) PTGS1PTGS2LMNAALDH1A1HPGD
SCHEMBL25244236 0.67 PTGS2 (0.42) PTGS1PTGS2BCL2L1ACHESLC6A3
SCHEMBL25215204 0.67 BCL2L1 (0.51) PTGS1PTGS2BCL2L1PTGESALOX5
SCHEMBL28783504 0.66 PTGS1 (0.36) PTGS1PTGS2SIRT2SIRT1
SCHEMBL30489334 0.66 PTGS1 (0.36) PTGS1PTGS2SIRT2SIRT1SLC6A3
SCHEMBL25254777 0.65 PTGS2 (0.43) PTGS1PTGS2BCL2L1SLC6A3GFER
SCHEMBL523660 0.65 PTGS2 (0.44) PTGS1PTGS2SIRT2SIRT1BCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028356-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS ABBVIE INC (US) 2026-01-29 US disclosed
US-20250066388-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS ABBVIE INC (US) 2025-02-27 US disclosed
CN-119053610-A 1,3,4, 7-Tetrahydro-2H-pyrrolo [3',2':5,6] pyrido [2,3-b ] [1,4] oxazepine Bcl-2 inhibitors 艾伯维公司 2024-11-29 CN disclosed
US-11964990-B2 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors ABBVIE INC. (US) 2024-04-23 US disclosed
US-20230234971-A1 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors ABBVIE INC. (US) 2023-07-27 US disclosed
US-20230234971-A1 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors ABBVIE INC. (US) 2023-07-27 US disclosed
WO-2023141536-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS ABBVIE INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028356-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS BCL9L, BCL2L2, BCL2L1 PTGS1 1044/4885PTGS2 744/4885SIRT2 819/4885
US-20250066388-A1 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS BCL9L, BCL2L1, BCL2L2 PTGS1 178/4885PTGS2 211/4885SIRT2 962/4885
US-20230234971-A1 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors BCL9L, BCL2L1, BCL2L2 PTGS1 178/4885PTGS2 211/4885SIRT2 962/4885
US-11964990-B2 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors BCL9L, BCL2L1, BCL9 PTGS1 187/4885PTGS2 211/4885SIRT2 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.